161 related articles for article (PubMed ID: 19879951)
1. Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence.
Loberiza FR; Lee SJ; Klein JP; Hassebroek A; Dehn JG; Frangoul HA; Hahn T; Hale G; Lazarus HM; LeMaistre CF; Maziarz RT; Rizzo JD; Majhail NS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):368-75. PubMed ID: 19879951
[TBL] [Abstract][Full Text] [Related]
2. Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence.
Rao K; Darrington DL; Schumacher JJ; Devetten M; Vose JM; Loberiza FR
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1508-14. PubMed ID: 18022581
[TBL] [Abstract][Full Text] [Related]
3. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
5. Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Khera N; Gooley T; Flowers MED; Sandmaier BM; Loberiza F; Lee SJ; Appelbaum F
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1319-1323. PubMed ID: 27013013
[TBL] [Abstract][Full Text] [Related]
6. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
[TBL] [Abstract][Full Text] [Related]
7. Second allogeneic hematopoietic cell transplantation for relapse after first allografts.
Gyurkocza B; Storb R; Chauncey TR; Maloney DG; Storer BE; Sandmaier BM
Leuk Lymphoma; 2019 Jul; 60(7):1758-1766. PubMed ID: 30668198
[TBL] [Abstract][Full Text] [Related]
8. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.
Inagaki J; Fukano R; Noguchi M; Okamura J
Int J Hematol; 2017 May; 105(5):676-685. PubMed ID: 28205066
[TBL] [Abstract][Full Text] [Related]
9. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis.
Bona K; Brazauskas R; He N; Lehmann L; Abdel-Azim H; Ahmed IA; Al-Homsi AS; Aljurf M; Arnold SD; Badawy SM; Battiwalla M; Beattie S; Bhatt NS; Dalal J; Dandoy CE; Diaz MA; Frangoul HA; Freytes CO; Ganguly S; George B; Gomez-Almaguer D; Hahn T; Kamble RT; Knight JM; LeMaistre CF; Law J; Lazarus HM; Majhail NS; Olsson RF; Preussler J; Savani BN; Schears R; Seo S; Sharma A; Srivastava A; Steinberg A; Szwajcer D; Wirk B; Yoshimi A; Khera N; Wood WA; Hashmi S; Duncan CN; Saber W
Blood; 2021 Jan; 137(4):556-568. PubMed ID: 33104215
[TBL] [Abstract][Full Text] [Related]
10. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.
Baker KS; Davies SM; Majhail NS; Hassebroek A; Klein JP; Ballen KK; Bigelow CL; Frangoul HA; Hardy CL; Bredeson C; Dehn J; Friedman D; Hahn T; Hale G; Lazarus HM; LeMaistre CF; Loberiza F; Maharaj D; McCarthy P; Setterholm M; Spellman S; Trigg M; Maziarz RT; Switzer G; Lee SJ; Rizzo JD
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1543-54. PubMed ID: 19896078
[TBL] [Abstract][Full Text] [Related]
11. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
12. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
13. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
[TBL] [Abstract][Full Text] [Related]
14. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
[TBL] [Abstract][Full Text] [Related]
15. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
Majhail NS; Brunstein CG; Tomblyn M; Thomas AJ; Miller JS; Arora M; Kaufman DS; Burns LJ; Slungaard A; McGlave PB; Wagner JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR).
Gabriel M; Shaw BE; Brazauskas R; Chen M; Margolis DA; Sengelov H; Dahlberg A; Ahmed IA; Delgado D; Lazarus HM; Gibson B; Myers KC; Kamble RT; Abdel-Mageed A; Li CK; Flowers MED; Battiwalla M; Savani BN; Majhail N; Shaw PJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1320-1326. PubMed ID: 28411175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
